Back To TOP

What We Offer

Herceptin Access Solutions offers services to help you navigate the access and reimbursement process. Click on the icons to visit the following sections of our website.

 


 

 

 

 

Coverage

Herceptin Access Solutions Specialists can help you with benefits and coverage issues such as benefits investigations and prior authorization.


 

 

 

Reimbursement

Herceptin Access Solutions Specialists can help you by guiding you through denials and appeals and proving billing and coding information.


 

 

 

Patient Assistance

Patient assistance offerings through Herceptin Access Solutions can help your patients obtain the therapy prescribed, regardless of their ability to pay.


 

 

 

Product Distribution

Get information on product distribution methods* and our Spoilage Replacement Program.*


 

 

 

My Patient Solutions

Manage patient access with this online patient management resource.


 

 

Communication Assistance Services

As part of our commitment to your patients, we offer language translation and hearing-impaired services to anyone calling Herceptin Access Solutions. This way, we can ensure individual communication needs are not a barrier to accessing our patient and practice support services. Our interpretation services are available for a variety of languages. In addition, telephone-to-telephone typewriter (TTY) services are available for hearing-impaired callers.

 

 

Learn More About
Herceptin
  • LEARN about treatment with Herceptin
  • FIND the right patient assistance program with our Compass for Patient Access tool
  • LEARN HOW the Genentech BioOncology Co-pay Card can help with the out-of-pocket costs for Herceptin
  • Download: new forms for enrollment in GATCF
  • Form Statement of Medical Necessity
  • Form Patient Authorization and Notice of Release of Information

Herceptin Indication and Important Safety Information

INDICATION

Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature*) breast cancer:

  • As part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
  • With docetaxel and carboplatin
  • As a single agent following multi-modality anthracycline-based therapy

* High-risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3.

Metastatic indication

Herceptin is indicated:

  • In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic breast cancer
  • As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease

Herceptin is indicated:

  • In combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease.

Boxed WARNINGS and Additional Important Safety Information

  • Herceptin administration can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving Herceptin with anthracycline-containing chemotherapy regimens. In a pivotal adjuvant breast cancer trial, one patient who developed CHF died of cardiomyopathy.
  • Evaluate cardiac function prior to and during treatment. For adjuvant breast cancer therapy, also evaluate cardiac function after completion of Herceptin. Discontinue Herceptin for cardiomyopathy.
  • Herceptin can result in serious and fatal infusion reactions and pulmonary toxicity. Discontinue Herceptin for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.
  • Exposure to Herceptin during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death.
  • Exacerbation of chemotherapy-induced neutropenia has also occurred.
  • Detection of HER2 protein overexpression is necessary for selection of patients appropriate for Herceptin therapy.
  • The most common adverse reactions associated with Herceptin in breast cancer were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.
  • The most common adverse reactions associated with Herceptin in metastatic gastric cancer were neutropenia, diarrhea, fatigue, anemia, stomatitis, weight loss, upper respiratory tract infections, fever, thrombocytopenia, mucosal inflammation, nasopharyngitis, and dysgeusia.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see the Herceptin full prescribing information including Boxed WARNINGS and additional important safety information.